CORT — CORCEPT THERAPEUTICS INC

Nasdaq · Health Care · Pharmaceuticals · CIK 1088856 ·
Last close
$123.24
Market Cap
$13.32B
52W High
$124.01
52W Low
$59.03
ADV30
1,165,892
Next earnings
2026-07-29
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 256,147,000 252,086,000 41,300,000 42,987,000 888,702,000 111,039,000 182,926,000
Mar 2026 164,903,000 162,020,000 -49,601,000 -31,761,000 814,881,000 108,738,000 176,894,000
Dec 2025 202,125,000 199,580,000 4,487,000 24,288,000 836,651,000 120,495,000 188,846,000
Sep 2025 207,638,000 203,042,000 10,219,000 19,668,000 823,607,000 125,138,000 191,705,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$109,700,000
Investing CF
$-21,898,000
Financing CF
$-78,906,000
CapEx
$-2,836,000
Dividends Paid
Buybacks
$0
EPS Diluted TTM
$0.42
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$654,613,000
Inventory
$13,185,000
Receivables
$76,920,000
ST Investments
$197,158,000
EBIT TTM
$6,405,000
Pretax Income TTM
$26,369,000
Interest Exp TTM
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$830,812,992
EBITDA
$8,084,000
Free Cash Flow
$77,395,128
Enterprise Value
$13,023,270,912
Total Cash
$308,196,992
Total Debt
$9,421,000
Shares Out
108,098,397
Trailing EPS
$0.46
Book Value
$6.54
ROE
8.2%
ROA
0.5%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 761,407,000 44,797,000 99,652,000 836,651,000 188,846,000 141,996,000
Dec 2024 675,040,000 136,951,000 141,209,000 840,553,000 160,964,000 198,295,000
Dec 2023 482,375,000 107,282,000 106,140,000 621,517,000 114,812,000 126,681,000
Dec 2022 401,858,000 112,634,000 101,418,000 583,430,000 81,588,000 120,323,000
Dec 2021

TTM Snapshot

Revenues TTM
$10,102,000
NetIncome TTM
$-4,830,000
OpCashFlow TTM
$0
Assets (Latest)
$51,902,000
Forward EPS
$4.40

Max Pain — expiry 2027-01-15

max pain strike: $82.50 · spot: $123.24 · call oi: 5,100 · put oi: 3,461
Expected Move to 2027-01-15: ±$43.62 (35.39%) — implied range $79.62$166.86 · ATM straddle on $125.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
BMRN BIOMARIN PHARMACEUTICAL INC $12.60B $65.07
ARWR ARROWHEAD PHARMACEUTICALS, INC. $12.22B $86.73
ELAN Elanco Animal Health Inc $12.20B $24.42
MDGL MADRIGAL PHARMACEUTICALS, INC. $11.83B $511.97
BBIO BridgeBio Pharma, Inc. $15.85B $81.07

News headlines (Yahoo Finance, 1h cache)

Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)
2026-08-20 17:15 · Yahoo
Corcept Therapeutics (CORT) Stock May Trade At A Discount Yet A Premium On Sales
2026-08-07 22:11 · Yahoo
Corcept Therapeutics Stock Shines at New All-Time Highs Despite Its Valuation
2026-08-05 14:15 · Yahoo
Corcept Therapeutics Inc (CORT) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
2026-07-30 05:01 · Yahoo
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates
2026-07-29 22:25 · Yahoo
Corcept (NASDAQ:CORT) Reports Bullish Q2 CY2026, Stock Jumps 17.4%
2026-07-29 20:14 · Yahoo
Spotting Winners: Corcept (NASDAQ:CORT) And Branded Pharmaceuticals Stocks In Q1
2026-07-29 01:57 · Yahoo
Corcept (CORT) Q2 Earnings: What To Expect
2026-07-28 14:21 · Yahoo
Why Corcept (CORT) Stock Is Down Today
2026-07-28 02:05 · Yahoo
Corcept Therapeutics (CORT) Is Up 5.3% After Analysts Lift Full-Year Earnings Outlook Significantly
2026-07-25 05:09 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.